colorectal cancer,lung cancer
Conditions
Interventions
Orally administer minocycline at 100 mg/day.
Orally administer doxycycline at 100 mg/day.
Sponsors
Saiseikai Yamaguchi General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients receiving treatment at Saiseikai Yamaguchi General Hospital. 2.Patients who were administered panitumumab, cetuximab, afatinib, erlotinib, osimertinib or amivantamab for the first time or after a period of time had passed and skin disorders had disappeared. 3.Have signed written informed consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1.Patients who could not continue treatment by the 12th week. 2.Patients who have developed skin disorders other than rash acneiform specific to EGFR inhibitors, such as toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). 3.Patients under 18 years of age.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of grade 2 (CTCAE v5.0) or higher rash acneiform within 12 weeks after starting EGFR molecular targeting drug administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Period until first appearance of rash acneiform by grade | — |
Countries
Japan
Contacts
Public ContactMiho Nishi
Saiseikai Yamaguchi General Hospital Department of Pharmacy
Outcome results
None listed